Complex Lobectomy in a Patient With Lung Cancer and Pulmonary Artery Sling

Marco Mammana1, Andrea Zuin1, Eugenio Serra2

  • 1Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padua, Italy.

Insights

Pulmonary artery sling, a rare congenital anomaly, is usually diagnosed in infancy. This report details an adult lung cancer case complicated by an undiagnosed pulmonary artery sling, necessitating complex surgery.

Area of Science:

  • Cardiology
  • Thoracic Surgery
  • Pulmonology

Background:

  • Pulmonary artery sling is a rare congenital anomaly.
  • It typically presents in infancy with respiratory distress.
  • Asymptomatic adult cases are uncommon.

Observation:

  • An adult patient with right upper lobe lung adenocarcinoma was found to have an undiagnosed pulmonary artery sling.
  • The tumor extended into the hilum and superior mediastinum.
  • This presented a unique surgical challenge due to the tumor's invasiveness and aberrant vasculature.

Findings:

  • The co-occurrence of lung adenocarcinoma and pulmonary artery sling in an adult is exceptionally rare.
  • Surgical management required intricate planning due to the complex anatomical relationship between the tumor and the anomalous pulmonary artery.
  • Multiple reconstructive procedures were necessary to address both the oncological and vascular aspects.

Implications:

  • This case highlights the importance of considering rare congenital anomalies in adult patients presenting with thoracic malignancies.
  • It underscores the need for advanced imaging and multidisciplinary approaches in managing complex surgical scenarios.
  • Such cases expand the understanding of pulmonary artery sling presentations and surgical considerations in adult oncology.

Related Concept Videos

Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
578
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
445
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
475
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
597
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
464